Cell Therapeutics ($CTIC) appeals FDA decision on pixantrone

Cell Therapeutics said today that, as planned, it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory aggressive non-Hodgkin's lymphoma. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.